Abstract Objective To investigate the association of serum vitamin D[25-(OH)D3] level with the severity and treatment in children with Henoch-Schönlein purpura (HSP). Methods A total of 50 children with newly-diagnosed HSP between January and December, 2015 were enrolled as HSP group, and 49 healthy children were enrolled as control group. Fasting serum samples were collected, and ELISA was used to measure serum 25-(OH)D3 level. According to the serum 25-(OH)D3 level, the HSP group were further divided into normal group (> 20 ng/mL) (n=9), insuffciency group (15-20 ng/mL) (n=15), defciency group (≤ 15 ng/mL) (n=25), and severe defciency group (≤ 5 ng/mL) (n=1). The general data, clinical manifestations, hormone therapy, course of disease before admission, and length of hospital stay were compared between groups. Results The HSP group had a signifcantly lower serum 25-(OH)D3 level than the control group (16±6 ng/mL vs 29±5 ng/mL; P < 0.01). Compared with the normal and insuffciency groups, the defciency and severe deficiency groups had significant increases in the incidence rate of renal involvement, rate of hormone application, and median length of hospital stay (P < 0.05), while there was no signifcant difference in course of disease before admission (P > 0.05). Conclusions Children with HSP have a low serum 25-(OH)D3 level, and such children may have a high risk of renal involvement, a high rate of hormone application, and a prolonged length of hospital stay. However, further studies are needed to investigate whether vitamin D supplementation is helpful to the treatment of HSP and can shorten the course of disease in children with HSP.
FAN Li,LIU Heng,WANG Yu-Chuan et al. Association of serum vitamin D level with severity and treatment in children with Henoch-Schönlein purpura[J]. CJCP, 2017, 19(7): 796-799.
FAN Li,LIU Heng,WANG Yu-Chuan et al. Association of serum vitamin D level with severity and treatment in children with Henoch-Schönlein purpura[J]. CJCP, 2017, 19(7): 796-799.
Iqbal SF, Freishtat RJ. Mechanism of action of vitamin D in the asthmatic lung[J]. J Investig Med, 2011, 59(8):1200-1202.
[3]
Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides[J]. Ann Rheum Dis, 2006, 65(7):936-941.
Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management:review of current knowledge and recommendations[J]. Pediatrics, 2008, 122(2):398-417.
Dimeloe S, Nanzer A, Ryanna K, et al. Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and vitamin D[J]. J Steroid Biochem Mol Biol, 2010, 120(2-3):86-95.
[10]
Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells[J]. J Cell Biochem, 2003, 89(5):922-932.
Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura[J]. J Pediatr, 2009, 155(1):136-139.
[14]
Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schönlein purpura in a 6-month prospective study of 223 children[J]. Arch Dis Child, 2010, 95(11):877-882.
